ICROM s.r.l. (“ICROM”), Italian leading API CDMO has acquired 100% of shares of HOLODIAG sas (“HOLODIAG”), the French leading expert CRO dedicated to pharma solid state and crystallization processes of small molecules. The acquisition of this technology platform is aligned with ICROM Group strategy to become a global leader CDMO for the innovative as well as for the generic pharma space.
ICROM is an API CDMO specialized in development and GMP manufacturing of potent and non-potent Active Ingredients. With over 50 years of experience, ICROM is the partner of choice for pharmaceutical outsourcing, able to provide a wide range of tailored services, custom development and custom manufacturing of NCEs as well as generic APIs. Leveraging sophisticated know-how, ICROM builds high-tech solutions to create complex molecules.
HOLODIAG is an expert CRO dedicated to solid state and crystallization of small molecules, operating mainly for pharmaceutical development. Founded in 2006 by Dr. Pierric Marchand, HOLODIAG holds laboratories fully equipped with state of the art analytical devices. Services provided include solid form analyses, solid form screenings and selections, crystallization process development, support and troubleshooting for formulation development; each of these is applicable to toxic and HP APIs.
Dr. Pierric Marchand, GM of Holodiag (on the left) and Pierfrancesco Morosini, President of Icrom Group (on the right)
"Pierric Marchand, General Manager of HOLODIAG, and his team of scientists bring an excellent experience and critical ‘know-how’ within the newly created ICROM Group. HOLODIAG has been highly successful in the pharma industry for almost 20 years in supporting the biopharmaceutical companies in the field of solid state characterization of their small molecules." said Pierfrancesco Morosini, President of Icrom Group.
We are very pleased to make available those highly technological services within the frame of the ICROM Group, aiming to a seamless provision of their technologies for the growth of both companies
According to Dr. Marchand, it was a natural and logical decision to join ICROM Group. "ICROM is well-known across the industry and its business operations, spread globally, create exceptional outsourcing opportunities for the biopharmaceutical companies to access complex APIs and high technological services which must be included in their CMC file. HOLODIAG operates at broad level in France and Europe and aims at expanding its activities at a wider scale. This acquisition will bring a series of synergies and pool resources with a significant growth in size and capabilities for HOLODIAG."
Exact terms of the transaction have not been made public.
